1.A Pilot Study of Trans-Arterial Injection of 166Holmium-Chitosan Complex for Treatment of Small Hepatocellular Carcinoma.
Byoung Chul CHO ; Eun Hee KIM ; Hye Jin CHOI ; Joo Hang KIM ; Jae Kyung ROH ; Hyun Cheol CHUNG ; Joong Bae AHN ; Jong Doo LEE ; Jong Tae LEE ; Nae Choon YOO ; Joo Hyuk SOHN
Yonsei Medical Journal 2005;46(6):799-805
Percutaneous approaches, such as percutaneous ethanol injection and radiofrequency ablation, have been most widely used for hepatocellular carcinoma patients who were not eligible for surgery. New technologies to improve the efficacy are currently needed. 166Holmium is a neutron activated radionuclide, and has several beneficial radiophysical characteristics for internal radiation therapy. 166Holmium-Chitosan complex, in which chitosan is chelated with 166Holmium, was developed as a radiopharmaceutical for cancer therapy. We have conducted a pilot study to evaluate the clinical efficacy of transarterial administration of 166Holmium-Chitosan complex in patients with a single and small (< 3 cm) hepatocellular carcinoma. 166Holmium-Chitosan complex, at a dose of 20 mCi per cm of tumor mass-diameter, was administered through the artery that directly fed the tumor. Twelve patients were treated with a median follow-up duration of 26 (range: 12-61) months. The tumor diameter ranged between 1.5 and 2.5 cm. Ten patients (83%) had complete response and two (17%) had partial response. The median complete response duration was not reached. The median AFP level declined from 83.8 to 8.3 ng/mL within 2 months after treatment. No grade III/IV toxicity was observed. Grade I and II toxicities were observed in four patients (2 abdominal pain, 1 fever, and 1 AST/ALT elevation). No toxic death occurred. This preliminary study shows a promising and durable complete response rate with an acceptable safety profile. Further studies with greater accrual of patients are warranted.
alpha-Fetoproteins/metabolism
;
Tomography, X-Ray Computed
;
Radiopharmaceuticals/administration & dosage/*therapeutic use
;
Pilot Projects
;
Middle Aged
;
Male
;
Liver Neoplasms/pathology/radiography/*radiotherapy
;
Injections, Intra-Arterial
;
Humans
;
Female
;
Chitosan/administration & dosage/*therapeutic use
;
Carcinoma, Hepatocellular/pathology/radiography/*radiotherapy
;
Aged
;
Adult
2.Influence of P53 on the radiotherapy response of hepatocellular carcinoma.
Ana R GOMES ; Ana M ABRANTES ; Ana F BRITO ; Mafalda LARANJO ; Joao E CASALTA-LOPES ; Ana C GONCALVES ; Ana B SARMENTO-RIBEIRO ; Maria F BOTELHO ; Jose G TRALHAO
Clinical and Molecular Hepatology 2015;21(3):257-267
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and it has a poor prognosis and few therapeutic options. Radiotherapy is one of the most effective forms of cancer treatment, and P53 protein is one of the key molecules determining how a cell responds to radiotherapy. The aim of this study was to determine the therapeutic efficacy of iodine-131 in three human HCC cell lines. METHODS: Western blotting was used to measure P53 expression. The effects of radiotherapy with iodine-131 were assessed by using the clonogenic assay to evaluate cell survival. Flow cytometry was carried out to examine the effects of iodine-131 on cell death, oxidative stress, reduced intracellular glutathione expression, the mitochondrial membrane potential, and the cell cycle. RESULTS: The P53 protein was not expressed in Hep3B2.1-7 cells, was expressed at normal levels in HepG2 cells, and was overexpressed in HuH7 cells. P53 expression in the HuH7 and HepG2 cell lines increased after internal and external irradiation with iodine-131. Irradiation induced a decrease in cell survival and led to a decrease in cell viability in all of the cell lines studied, accompanied by cell death via late apoptosis/necrosis and necrosis. Irradiation with 131-iodine induced mostly cell-cycle arrest in the G0/G1 phase. CONCLUSIONS: These results suggest that P53 plays a key role in the radiotherapy response of HCC.
Apoptosis/*radiation effects
;
Blotting, Western
;
Carcinoma, Hepatocellular/metabolism/pathology/radiotherapy
;
Cell Line, Tumor
;
Cell Survival/drug effects
;
G1 Phase Cell Cycle Checkpoints/radiation effects
;
*Gamma Rays
;
Glutathione/metabolism
;
Hep G2 Cells
;
Humans
;
Iodine Radioisotopes/chemistry/pharmacology/therapeutic use
;
Liver Neoplasms/metabolism/pathology/radiotherapy
;
Phosphorylation
;
Reactive Oxygen Species/metabolism
;
Tumor Suppressor Protein p53/*metabolism
3.A case of isolated metastatic hepatocellular carcinoma arising from the pelvic bone.
Kyu Sik JUNG ; Kyeong Hye PARK ; Young Eun CHON ; Sa Ra LEE ; Young Nyun PARK ; Do Yun LEE ; Jin Sil SEONG ; Jun Yong PARK
The Korean Journal of Hepatology 2012;18(1):89-93
Reports of metastatic hepatocellular carcinoma (HCC) without a primary liver tumor are rare. Here we present a case of isolated HCC that had metastasized to the pelvic bone without a primary focus. A 73-year-old man presented with severe back and right-leg pain. Radiological examinations, including computed tomography (CT) and magnetic resonance imaging (MRI), revealed a huge mass on the pelvic bone (13x10 cm). He underwent an incisional biopsy, and the results of the subsequent histological examination were consistent with metastatic hepatocellular carcinoma. The tumor cells were positive for cytokeratin (AE1/AE3), hepatocyte paraffin 1, and glypican-3, and negative for CD56, chromogranin A, and synaptophysin on immunohistochemical staining. Examination of the liver by CT, MRI, positron-emission tomography scan, and angiography produced no evidence of a primary tumor. Radiotherapy and transarterial chemoembolization were performed on the pelvic bone, followed by systemic chemotherapy. These combination treatments resulted in tumor regression with necrotic changes. However, multiple lung metastases developed 1 year after the treatment, and the patient was treated with additional systemic chemotherapy.
Aged
;
Bone Neoplasms/*diagnosis/*pathology/radiotherapy
;
Carcinoma, Hepatocellular/*pathology/radiography/*secondary
;
Chemoembolization, Therapeutic
;
Combined Modality Therapy
;
Glypicans/metabolism
;
Humans
;
Keratin-1/metabolism
;
Keratin-3/metabolism
;
Liver Neoplasms/*pathology/radiography/*secondary
;
Magnetic Resonance Imaging
;
Male
;
Paraffin/metabolism
;
Pelvic Bones/*pathology/radiography
;
Positron-Emission Tomography
;
Tomography, X-Ray Computed